NetworkNewsBreaks – Nemaura Medical Inc. (NASDAQ
Post# of 73
(Total Views: 194)
Posted On: 09/27/2021 4:06:13 PM
NetworkNewsBreaks – Nemaura Medical Inc. (NASDAQ: NMRD) Enters Strategic Commercial Agreement with UK Licensee
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). Under the agreement, the continuous glucose monitor (“CGM”) and sensors will be provided as duo packs with prescription only medicines that are widely prescribed for people with type 2 diabetes. MSW-DP has been granted global rights to the sugarBEAT(R) non-invasive CGM devices and sensors, to be provided solely as duo packs with these medicines, under the terms of the agreement, which Nemaura will sell to MSW-DP under the license agreement. “We look forward to this exciting partnership whereupon sugarBEAT products will support the care of patients with type 2 diabetes. It is important that patients have a more convenient way to monitor the effectiveness of their therapeutic treatments without the hassle of repeated finger pricks and other invasive techniques,” said Nemaura CEO Dr. Faz Chowdhury. “We look forward to continuing to innovate and develop solutions for patients across the world.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Nemaura Medical (NASDAQ: NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coaching programs, today announced its entry into a global commercial contract with MySugarWatch DuoPack Limited (“MSW-DP”). Under the agreement, the continuous glucose monitor (“CGM”) and sensors will be provided as duo packs with prescription only medicines that are widely prescribed for people with type 2 diabetes. MSW-DP has been granted global rights to the sugarBEAT(R) non-invasive CGM devices and sensors, to be provided solely as duo packs with these medicines, under the terms of the agreement, which Nemaura will sell to MSW-DP under the license agreement. “We look forward to this exciting partnership whereupon sugarBEAT products will support the care of patients with type 2 diabetes. It is important that patients have a more convenient way to monitor the effectiveness of their therapeutic treatments without the hassle of repeated finger pricks and other invasive techniques,” said Nemaura CEO Dr. Faz Chowdhury. “We look forward to continuing to innovate and develop solutions for patients across the world.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Nemaura Medical Inc. (NMRD) Stock Research Links
Scroll down for more posts ▼